Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 26, 2019- On Women's Equality Day, Abbott is publishing a blueprint for creating a high school STEM internship aimed at exposing young people, particularly girls, to STEM early and empowering other companies to download and use it- More than half of girls in a YouGov-Abbott survey say they aren't encouraged to study STEM, but 89% of girls who are urged to study STEM say they plan to pursue it in their educations
- Jul 17, 2019- Accelerated and sustainable growth driven by strong performance across portfolio- Raising full-year guidance for organic sales growth to 7 to 8 percent- Double-digit EPS growth exceeded expectations; raising full-year forecast- Long-term growth drivers - FreeStyle Libre, MitraClip and Alinity - achieving exceptional growth
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
-
Jun 18, 2019- Heart failure is a manageable condition, especially if it is detected early, but people are shying away from a conversation with their doctor because they are afraid of the diagnosis- Abbott, the global leader in heart failure treatment and technologies, is using this information to increase awareness and patient-physician dialogue as heart failure diagnoses are expected to rise 46% by 2030
- Jun 13, 2019- 45% of blood donations have historically come from people over 50 years old, but that number is declining1- As more millennials bring their passion to blood donation, they can fill the gap left by aging baby boomers- Abbott, the global leader in blood screening, is asking people of all generations to sign up to give blood and help save a life on World Blood Donor Day, June 14, and throughout the year
- May 15, 2019- The YouGov-Abbott Student Loan Impact Survey shows 87% of those in college or graduating this year with student debt say finding a company with a student loan benefit is important to them- Additionally, over 6 in 10 working adults with student loans would consider switching to a company with a student loan employee benefit
- Apr 30, 2019-- Academic, military and healthcare leaders have come together to conduct a scientifically rigorous clinical trial of a blood test in development for the brain-- Research could lead to the first point-of-care blood test of its kind to help evaluate concussions within minutes
- Jan 23, 2019- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent- Issues financial outlook for 2019, reflecting double-digit EPS growth and 6.5 to 7.5 percent organic sales growth
- Jan 16, 2019Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment
-
Nov 15, 2018New White Paper Shares Research Findings on Perceptions and Awareness of Medical Device Cybersecurity, Need for Collaboration to Address Cybersecurity Challenges
-
Oct 17, 2018- Third-quarter reported sales growth of 12.1 percent; organic sales growth of 7.8 percent- Third-quarter GAAP EPS from continuing operations of $0.31; adjusted EPS from continuing operations of $0.75- Strong growth and pipeline advancements across portfolio
-
Oct 15, 2018- Mr. Ford, a 22-year Abbott veteran, is currently executive vice president of Medical Devices, Abbott's largest business- Mr. Ford will expand his current role, taking on responsibility for all of Abbott's operating businesses
-
Sep 13, 2018- Company achieves more than double the overall average industry score and maintains top industry scores in economic and social performance- Abbott recognized for sustainability on DJSI for 14 consecutive years
-
Aug 3, 2018Global recognition for cross-functional care teams achieving measurably better healthcareNow accepting applications to celebrate unity and change in healthcare
-
Jun 26, 2018- Two-Thirds of Millennials Aren't Saving for Retirement- Benefit Means Student Debt Won't Prevent Retirement Savings
-
May 4, 2018- Abbott previously communicated safety alert related to potential outflow graft twisting to physicians on April 5, 2018
-
Apr 17, 2018- Latest in planned series of cybersecurity updates further strengthens security and performance of implantable cardioverter defibrillators- Part of Abbott’s ongoing commitment to continuously advance the security of connected devices and systems
-
Feb 27, 2018- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U.- AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT'S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS' PROPRIETARY DRUG-DELIVERY AND WHOLE-PRODUCT SOLUTIONS STRATEGY
-
Aug 29, 2017-Planned updates designed to provide new patient management tools and further protection against unauthorized access- Updates part of ongoing effort to continuously improve patient care
Jul 13, 2017- Agreement promises major leap forward in automation of diabetes management- Abbott will supply Bigfoot with the next generation of its FreeStyle® Libre glucose sensing technology for clinical and commercial use
Apr 26, 2017-Research shows that staying nourished in the days and hours prior to a procedure can help patients prepare for and recover from surgery- New Ensure® Surgery Immunonutrition Shake and Ensure® Pre-Surgery Clear Nutrition Drink are designed for hospitals implementing surgical guidelines for enhancing patient recovery
- Jan 25, 2017- Fourth-quarter GAAP EPS from continuing operations of $0.51; adjusted EPS from operations of $0.65- Issues EPS outlook for 2017, reflecting double-digit growth at the mid-point- Completed acquisition of St. Jude Medical, creating a premier medical device business with leading positions in several large and high-growth areas